UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 422

Sortiert nach

The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials

Hepatology (Baltimore, Md.), 2019-12, Vol.70 (6), p.1913-1927

2019

Link zum Volltext

Verfügbarkeit prüfen

Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study

The Lancet (British edition), 2013-02, Vol.381 (9865), p.468-475

2013

Link zum Volltext

Verfügbarkeit prüfen

Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options

The New England journal of medicine, 2013-05, Vol.368 (20), p.1867-1877

2013

Link zum Volltext

Verfügbarkeit prüfen

Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial

The Lancet (British edition), 2014-02, Vol.383 (9916), p.515-523

2014

Link zum Volltext

Verfügbarkeit prüfen

Sofosbuvir and Ribavirin Prevent Recurrence of HCV Infection After Liver Transplantation: An Open-Label Study

Gastroenterology (New York, N.Y. 1943), 2015, Vol.148 (1), p.100-107.e1

2015

Link zum Volltext

Verfügbarkeit prüfen

American Gastroenterological Association Technical Review on the Management of Hepatitis C

Gastroenterology (New York, N.Y. 1943), 2006-01, Vol.130 (1), p.231-264

2006

Link zum Volltext

Verfügbarkeit prüfen

An Exome Sequencing Study to Assess the Role of Rare Genetic Variation in Pulmonary Fibrosis

American journal of respiratory and critical care medicine, 2017-07, Vol.196 (1), p.82-93

2017

Link zum Volltext

Verfügbarkeit prüfen

Ethical and Scientific Implications of the Globalization of Clinical Research

The New England journal of medicine, 2009-02, Vol.360 (8), p.816-823

2009

Link zum Volltext

Verfügbarkeit prüfen

Sofosbuvir and Ribavirin for Treatment of Compensated Recurrent Hepatitis C Virus Infection After Liver Transplantation

Gastroenterology (New York, N.Y. 1943), 2015, Vol.148 (1), p.108-117

2015

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of Nucleotide Polymerase Inhibitor Sofosbuvir Plus the NS5A Inhibitor Ledipasvir or the NS5B Non-Nucleoside Inhibitor GS-9669 Against HCV Genotype 1 Infection

Gastroenterology (New York, N.Y. 1943), 2014-03, Vol.146 (3), p.736-743.e1

2014

Link zum Volltext

Verfügbarkeit prüfen

Replicated Association Between an IL28B Gene Variant and a Sustained Response to Pegylated Interferon and Ribavirin

Gastroenterology (New York, N.Y. 1943), 2010-06, Vol.138 (7), p.2307-2314

2010

Link zum Volltext

Verfügbarkeit prüfen

Genetic variation in IL28B and spontaneous clearance of hepatitis C virus

Nature (London), 2009-10, Vol.461 (7265), p.798-801

2009

Link zum Volltext

Verfügbarkeit prüfen

Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection

Journal of hepatology, 2015-03, Vol.62 (3), p.533-540

2015

Link zum Volltext

Verfügbarkeit prüfen

The Hepatitis C Virus Life Cycle as a Target for New Antiviral Therapies

Gastroenterology (New York, N.Y. 1943), 2007-05, Vol.132 (5), p.1979-1998

2007

Link zum Volltext

Verfügbarkeit prüfen

Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study

The Lancet (British edition), 2015-03, Vol.385 (9973), p.1098-1106

2015

Link zum Volltext

Verfügbarkeit prüfen

L159F and V321A Sofosbuvir-Associated Hepatitis C Virus NS5B Substitutions

The Journal of infectious diseases, 2016-04, Vol.213 (8), p.1240-1247

2016

Link zum Volltext

Verfügbarkeit prüfen

Safety, tolerability and immunogenicity of GS-4774, a hepatitis B virus-specific therapeutic vaccine, in healthy subjects: A randomized study

Vaccine, 2014-09, Vol.32 (39), p.4925-4931

2014

Link zum Volltext

Verfügbarkeit prüfen

Variants in the ITPA Gene Protect Against Ribavirin-Induced Hemolytic Anemia and Decrease the Need for Ribavirin Dose Reduction

Gastroenterology (New York, N.Y. 1943), 2010-10, Vol.139 (4), p.1181-1189.e2

2010

Link zum Volltext

Verfügbarkeit prüfen

Characterization of hepatitis C virus intergenotypic recombinant strains and associated virological response to sofosbuvir/ribavirin

Hepatology (Baltimore, Md.), 2015-02, Vol.61 (2), p.471-480

2015

Link zum Volltext

Verfügbarkeit prüfen

Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug‐induced liver injury

Hepatology (Baltimore, Md.), 2008-10, Vol.48 (4), p.1175-1183

2008

Link zum Volltext

Verfügbarkeit prüfen

Inosine Triphosphate Protects Against Ribavirin-Induced Adenosine Triphosphate Loss by Adenylosuccinate Synthase Function

Gastroenterology (New York, N.Y. 1943), 2011-04, Vol.140 (4), p.1314-1321

2011

Link zum Volltext

Verfügbarkeit prüfen

Hepatitis C pharmacogenetics: State of the art in 2010

Hepatology (Baltimore, Md.), 2011-01, Vol.53 (1), p.336-345

2011

Link zum Volltext

Verfügbarkeit prüfen

Development and validation of a primary sclerosing cholangitis–specific patient‐reported outcomes instrument: The PSC PRO

Hepatology (Baltimore, Md.), 2018-07, Vol.68 (1), p.155-165

2018

Link zum Volltext

Verfügbarkeit prüfen

Will IL28B polymorphism remain relevant in the era of direct-acting antiviral agents for hepatitis C virus?

Hepatology (Baltimore, Md.), 2012-07, Vol.56 (1), p.373-381

2012

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 422

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(385)
Mit Volltextzugriff
(380)

Publikationsform

Artikel
(390)
Buchkapitel
(31)
Bücher
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(314)
Life Sciences & Biomedicine
(309)
Humans
(291)
Male
(217)
Female
(214)
Gastroenterology & Hepatology
(203)
Middle Aged
(195)
Adult
(176)
Hepatitis C, Chronic - Drug Therapy
(148)
Antiviral Agents - Therapeutic Use
(142)
Biological And Medical Sciences
(128)
Medical Sciences
(124)
Hepacivirus - Genetics
(122)
Infectious Diseases
(120)
Genotype
(118)
Hepatitis C Virus
(106)
Treatment Outcome
(104)
Hepatitis C
(102)
Aged
(100)
Drug Therapy, Combination
(97)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials

Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study

Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options

Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial

Sofosbuvir and Ribavirin Prevent Recurrence of HCV Infection After Liver Transplantation: An Open-Label Study

American Gastroenterological Association Technical Review on the Management of Hepatitis C

An Exome Sequencing Study to Assess the Role of Rare Genetic Variation in Pulmonary Fibrosis

Ethical and Scientific Implications of the Globalization of Clinical Research

Sofosbuvir and Ribavirin for Treatment of Compensated Recurrent Hepatitis C Virus Infection After Liver Transplantation

Efficacy of Nucleotide Polymerase Inhibitor Sofosbuvir Plus the NS5A Inhibitor Ledipasvir or the NS5B Non-Nucleoside Inhibitor GS-9669 Against HCV Genotype 1 Infection

Replicated Association Between an IL28B Gene Variant and a Sustained Response to Pegylated Interferon and Ribavirin

Genetic variation in IL28B and spontaneous clearance of hepatitis C virus

Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection

The Hepatitis C Virus Life Cycle as a Target for New Antiviral Therapies

Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study

L159F and V321A Sofosbuvir-Associated Hepatitis C Virus NS5B Substitutions

Safety, tolerability and immunogenicity of GS-4774, a hepatitis B virus-specific therapeutic vaccine, in healthy subjects: A randomized study

Variants in the ITPA Gene Protect Against Ribavirin-Induced Hemolytic Anemia and Decrease the Need for Ribavirin Dose Reduction

Characterization of hepatitis C virus intergenotypic recombinant strains and associated virological response to sofosbuvir/ribavirin

Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug‐induced liver injury

Inosine Triphosphate Protects Against Ribavirin-Induced Adenosine Triphosphate Loss by Adenylosuccinate Synthase Function

Hepatitis C pharmacogenetics: State of the art in 2010

Development and validation of a primary sclerosing cholangitis–specific patient‐reported outcomes instrument: The PSC PRO

A whole recombinant yeast-based therapeutic vaccine elicits HBV X, S and Core specific T cells in mice and activates human T cells recognizing epitopes linked to viral clearance

Will IL28B polymorphism remain relevant in the era of direct-acting antiviral agents for hepatitis C virus?

Suchergebnisse filtern